Home > Insider Trading > Filing (0001209191-20-025937)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
875320	Vertex Pharmaceuticals Inc / Ma	VRTX	Pharmaceutical Preparations (2834)	043039129

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1334365	Yuchun Lee	C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-04-24	2,000	$57.27	3,875	No	4	M	Direct
Common Stock	Disposition	2020-04-24	890	$267.23	2,985	No	4	S	Direct
Common Stock	Disposition	2020-04-24	590	$268.31	2,395	No	4	S	Direct
Common Stock	Disposition	2020-04-24	400	$269.28	1,995	No	4	S	Direct
Common Stock	Disposition	2020-04-24	120	$270.30	1,875	No	4	S	Direct
Common Stock	Acquisiton	2020-04-27	2,000	$57.27	3,875	No	4	M	Direct
Common Stock	Disposition	2020-04-27	193	$268.40	3,682	No	4	S	Direct
Common Stock	Disposition	2020-04-27	394	$270.37	3,288	No	4	S	Direct
Common Stock	Disposition	2020-04-27	1,113	$271.56	2,175	No	4	S	Direct
Common Stock	Disposition	2020-04-27	200	$272.51	1,975	No	4	S	Direct
Common Stock	Disposition	2020-04-27	100	$273.44	1,875	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2020-04-24	2,000	$0.00	2,000	$57.27
Common Stock	Stock Option (Right to Buy)	Disposition	2020-04-27	2,000	$0.00	2,000	$57.27

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
3,125		2022-09-13	No	4	M	Direct
1,125		2022-09-13	No	4	M	Direct

Footnotes

Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $267.23 (range $266.72 to $267.71).
Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $268.31 (range $267.94 to $268.77).
Open market sales reported on this line occurred at a weighted average price of $269.28 (range $269.00 to $269.64).
Open market sales reported on this line occurred at a weighted average price of $270.30 (range $270.05 to $270.33).
Open market sales reported on this line occurred at a weighted average price of $268.40 (range $268.05 to $268.77).
Open market sales reported on this line occurred at a weighted average price of $270.37 (range $270.08 to $270.78).
Open market sales reported on this line occurred at a weighted average price of $271.56 (range $271.12 to $272.00).
Open market sales reported on this line occurred at a weighted average price of $272.51 (range $272.31 to $272.71).
Fully vested.